Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Galenica AG ( (CH:GALE) ) has shared an announcement.
Galenica AG reported a 4.7% increase in revenue to CHF 1,314.2 million for the first four months of 2025, driven by strong demand for GLP-1-based weight loss products and a robust flu season boosting prescription drug sales. The company confirmed its financial outlook for 2025, expecting revenue growth of 3-5% and EBIT growth of 4-6%, indicating a positive trajectory in its market positioning. The growth was supported by various segments, including Products & Care and Logistics & IT, with notable contributions from local pharmacies and wholesale operations.
The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF89.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.
More about Galenica AG
Galenica AG is a Swiss company operating in the healthcare sector, providing a range of services including pharmacies, pharmaceutical logistics, and home care. With a workforce of approximately 8,000 employees, the company is committed to enhancing health and well-being in Switzerland. Galenica is listed on the Swiss stock exchange and is known for its extensive network and expertise in the healthcare market.
Average Trading Volume: 118,173
Current Market Cap: CHF4.32B
For detailed information about GALE stock, go to TipRanks’ Stock Analysis page.